Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Proteomic and phytohormone analysis of the response of maize ( Zea mays L.) seedlings to Sugarcane mosaic virus
Managing Side Effects While Away One of the challenges of weight loss medications like semaglutide is the potential for gastrointestinal side effects, such as nausea, bloating, or changes in bowel habits
Zhang C, Liu Z, Wang F, Zhang B, Zhang X, Guo P, et al
J.HansonR
116(8): 880881.Google ScholarPubMed Leis-Dosil, V.M., Alijo-Serrano, F., Aviles-Izquierdo, J.A., Lazaro-Ochaita, P., Lecona-Echeverria, M